MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)

Inclusion Criteria: * One of the following histologically or cytologically confirmed, advanced (unresectable or metastatic) solid tumors: * Squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix * Endometrial cancer * Head and neck squamous cell carcinoma (HNSCC) * Unresectable biliary adenocarcinoma (gallbladder or biliary tree \[intrahepatic or extrahepatic\] cholangiocarcinoma) * Adenocarcinoma or squamous cell carcinoma of the esophagus or advanced/metastatic Siewert type 1 adenocarcinoma of the gastroesophageal junction (GEJ). * Triple-negative breast cancer (TNBC) * Hepatocellular carcinoma (HCC) * Urothelial carcinoma of the renal pelvis, ureter, bladder, or urethra * Ovarian cancer * Gastric cancer * Measurable disease per RECIST v1.1 as assessed by BICR or local site investigator. * Adequately controlled blood pressure (BP) with or without antihypertensive medications. * Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on anti-retroviral therapy (ART). * Male participants must agree to follow contraceptive guidance. * Female participants are not pregnant or breastfeeding, not a woman of child-bearing potential (WOCBP) or is a WOCBP and agrees to follow contraceptive guidance. * Adequate organ function. Exclusion Criteria: * History of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 3 years. * Prior therapy with anti…